A novel inhibitor targeting matrix accumulation in cancer
Medicine : Therapeutics
Medicine : Animal Models
Nucleic Acid-, Protein and Cell-related Technologies
Scientists of the Max-Planck-Institute of Biochemistry have identified a unique cyclic molecule that diminishes extracellular matrix production thereby reducing tumor growth in cancer with no toxicity. Our scientists have validated the reduction of tumor growth in the presence of the molecule in two distinct models: breast cancer and melanoma.
Toxicity studies in mice revealed that the molecule did not affect blood cell count, liver or kidney function. Therefore, it is a promising candidate in cancer therapy.
We are looking for a collaboration partner to further develop this exciting project.
EP priority application was filed on 31.07.2019 followed by an international patent application PCT/EP2020/071319 that was filed on 28.07.2020.
- Ref.-No.: 0105-5855_1-IKF (326.4 KiB)
Dr. Ingrid Kapser-Fischer
Phone: +49 89 / 29 09 19-19